Imatron sells two more HeartScan centers

Article

Less than a month after it agreed to sell its South San Francisco HeartScan center, Imatron has found a buyer for two of its remaining three facilities. The South San Francisco ultrafast CT developer signed an agreement March 22 with Newport Beach,

Less than a month after it agreed to sell its South San Francisco HeartScan center, Imatron has found a buyer for two of its remaining three facilities. The South San Francisco ultrafast CT developer signed an agreement March 22 with Newport Beach, CA-based firm Vital Imaging Companies for the sale of its Houston and Washington, DC, coronary artery disease risk-assessment centers. Imatron expects the sale to close by March 31.

Imatron sold the South San Francisco center Feb. 25 to Imaging Technology Group, also of South San Francisco, for $1.5 million in cash (SCAN 3/17/99). The sale represented a shift in Imatron's corporate strategy: Rather than trying to sell the HeartScan subsidiary whole, the company decided to sell each center individually.

Vital Imaging Companies includes Vital Imaging, a California firm that is not related to 3-D workstation developer Vital Images of Minneapolis. Vital Imaging intends to establish a network of facilities in major cities across the U.S., and plans to open a center this August in San Diego, according to Richard King, chairman and CEO. Vital Imaging would like to expand the scope of service at its centers to include full-body scans and open MRI, King said.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.